Treatment with surufatinib, a VEGFR, FGFR, and CSF-1R inhibitor, prolonged progression-free survival in patients with pancreatic NETs, meeting the primary end point of the pre-planned interim analysis for the phase III SANET-p trial (NCT02589821). This positive results led to early study completion, at the recommendation of the Independent Data Monitoring Committee.2 The full results from the study will be presented at an upcoming medical conference. Read more . . .